NEW YORK, NY--(Marketwire - June 21, 2010) - Taglich Brothers, Inc. announces it initiated coverage of Competitive Technologies, Inc.

Competitive Technologies, Inc. (NYSE Amex: CTT), headquartered in Fairfield, Connecticut, offers technology transfer services. CTT licenses technologies from clients, obtaining licenses or rights to intellectual property on a broad array of technologies from universities, companies, inventors and patent or intellectual property holders. The company's intellectual property portfolio includes rights to technology in life sciences (healthcare), electronics, nano science and physical sciences.

Licenses and rights licensed by CTT from clients are in turn licensed or sub-licensed to customers, including large multinationals seeking to augment their product development efforts and enlarge their pipelines. Customers pay CTT license fees, royalties, or a share of per procedure or per unit revenue. Since its inception, CTT has licensed nearly 500 technologies to corporations and shared over $100 million in shared technology revenues with universities and inventors.

Near-term growth efforts are based on the commercialization of a medical device that CTT acquired rights to in 2007. The product, FDA-approved and CE marked, is eligible for regulatory clearance in most of the world's major medical markets. The MC5-A, also known as the Calmare Pain Therapy device, could potentially gain wide acceptance as a treatment for neuropathic and oncologic pain that has not responded to pharmaceutical or device-based pain therapy.

The complete 20-page report is available at

We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the company mentioned in this report.

All research issued by Taglich Brothers, Inc. is based on public information. In April 2010 the company paid an initial monetary engagement fee of US$2,000 to Taglich Brothers, Inc. representing payment for the first month of creation and dissemination of research reports, after which the company will pay Taglich Brothers, Inc. a monetary fee of US$2,000 per month for such services.

Contact Information:

Richard Oh
Taglich Brothers, Inc.